Free Trial

24,800 Shares in Corcept Therapeutics Incorporated (NASDAQ:CORT) Acquired by Versor Investments LP

Corcept Therapeutics logo with Medical background

Versor Investments LP acquired a new position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 24,800 shares of the biotechnology company's stock, valued at approximately $1,148,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Capital Performance Advisors LLP acquired a new position in Corcept Therapeutics in the 3rd quarter valued at about $25,000. Park Place Capital Corp acquired a new stake in shares of Corcept Therapeutics in the 2nd quarter valued at $32,000. Atwood & Palmer Inc. bought a new position in Corcept Therapeutics in the second quarter valued at about $35,000. Kathleen S. Wright Associates Inc. acquired a new stake in shares of Corcept Therapeutics in the 3rd quarter valued at approximately $36,000. Finally, Blue Trust Inc. increased its position in Corcept Therapeutics by 125.4% during the 2nd quarter. Blue Trust Inc. now owns 3,526 shares of the biotechnology company's stock valued at $115,000 after purchasing an additional 1,962 shares during the period. 93.61% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Corcept Therapeutics

In related news, insider William Guyer sold 10,000 shares of the business's stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $35.30, for a total transaction of $353,000.00. Following the sale, the insider now owns 6,039 shares of the company's stock, valued at approximately $213,176.70. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, insider Gary Charles Robb sold 3,101 shares of the business's stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $35.71, for a total transaction of $110,736.71. Following the completion of the sale, the insider now owns 23,190 shares of the company's stock, valued at $828,114.90. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider William Guyer sold 10,000 shares of the firm's stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $35.30, for a total transaction of $353,000.00. Following the transaction, the insider now directly owns 6,039 shares in the company, valued at approximately $213,176.70. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 34,101 shares of company stock worth $1,462,517. 20.50% of the stock is currently owned by insiders.

Corcept Therapeutics Stock Down 2.2 %

Shares of CORT stock traded down $1.27 during trading hours on Tuesday, reaching $57.79. 1,159,312 shares of the company's stock were exchanged, compared to its average volume of 1,191,102. The stock has a market cap of $6.06 billion, a PE ratio of 46.87 and a beta of 0.45. The company has a current ratio of 3.70, a quick ratio of 3.64 and a debt-to-equity ratio of 0.01. The stock's fifty day moving average price is $44.79 and its two-hundred day moving average price is $36.09. Corcept Therapeutics Incorporated has a 1 year low of $20.84 and a 1 year high of $61.66.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.27 by $0.14. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The company had revenue of $182.55 million for the quarter, compared to analyst estimates of $171.97 million. During the same quarter last year, the business earned $0.28 earnings per share. The firm's revenue was up 47.7% on a year-over-year basis. Research analysts predict that Corcept Therapeutics Incorporated will post 1.31 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on CORT. Sandler O'Neill reissued a "buy" rating on shares of Corcept Therapeutics in a research report on Friday, October 18th. Piper Sandler upped their target price on Corcept Therapeutics from $38.00 to $67.00 and gave the stock an "overweight" rating in a research note on Wednesday, September 18th. Truist Financial upped their price objective on shares of Corcept Therapeutics from $65.00 to $76.00 and gave the company a "buy" rating in a research note on Monday, September 30th. HC Wainwright reissued a "buy" rating and set a $80.00 price objective on shares of Corcept Therapeutics in a research report on Thursday, October 31st. Finally, StockNews.com upgraded Corcept Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Thursday, October 31st. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Corcept Therapeutics presently has an average rating of "Buy" and a consensus price target of $65.25.

View Our Latest Analysis on CORT

Corcept Therapeutics Company Profile

(Free Report)

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

See Also

Institutional Ownership by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Should you invest $1,000 in Corcept Therapeutics right now?

Before you consider Corcept Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corcept Therapeutics wasn't on the list.

While Corcept Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Why Whitestone REIT is Outperforming in 2024: 35% Growth & Monthly Dividends
Why SoundHound Stock Dip Could Mean Big Gains for 2025 Investors
Nintendo Stock: Buy Before the 2025 Switch Platform Hits!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines